Experimental drug aims to improve breathing in lung sarcoidosis
NCT ID NCT07680166
First seen Jul 02, 2026 · Last updated Jul 02, 2026
Summary
This study tests an investigational drug called XTMAB-16 in people with pulmonary sarcoidosis, a condition that causes inflammation and scarring in the lungs. The trial aims to see if the drug can improve lung function (measured by forced vital capacity) and quality of life. Participants receive either XTMAB-16 or a placebo by infusion, and the study includes both dose-finding and efficacy evaluation phases.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
XTMAB-16
What this could lead to
If successful, this could provide a new treatment option to improve lung function and quality of life for people with pulmonary sarcoidosis.
What could go wrong
This is an early-phase trial combining dose-finding and initial efficacy testing, so results may not confirm benefit. Side effects are still being evaluated.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PULMONARY SARCOIDOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Efzofitimod for Pulmonary Sarcoidosis Trial NCT05415137
- Acthar Gel for Sarcoidosis: CXCL9 Biomarker Stud NCT02523092
- OATD-01 for Pulmonary Sarcoidosis Trial (NCT06205121)
- FMT for Inflammatory Diseases Trial (NCT04924270)
- Sarcoidosis Medication Adherence Study | NCT05438095
- XTMAB-16 for Pulmonary Sarcoidosis Trial (NCT05890729)